INSIGHTS ON SOLID DOSE MANUFACTURING

• How To Avoid Sticking And Picking In The Tableting Industry

  Review strategies to mitigate sticking and picking risks in the tablet industry, and learn how you can foster improved tablet production processes, ensuring higher quality and consistency.

• Minitablets: Enhancing Safety And Palatability For Pediatric Medicines

  Leverage minitablet technology to create flexible, easy-to-swallow, and palatable pediatric formulations that improve adherence and meet evolving regulatory requirements.

• Achieving Licensing For A Healthcare Solution

  Facing strict regulations and tricky powders, a healthcare client sought an advanced filling solution. Learn how an expert collaboration led to licensed product, boosting precision and productivity.

• Lower Punch Tip Bending / Buckling

  When manufacturing mini-tablets, adjusting punch force ratings is crucial to prevent bending or buckling. The Rankine-Gordon formula offers a safer force rating for microtip tooling.

• Engineering Challenges Of Designing Pharmaceutical Isolators

  3/27/2025

  Designing pharmaceutical isolators requires navigating complex engineering hurdles, from ensuring chemical compatibility to optimizing airflow and pressure. Explore the critical considerations that guarantee drug manufacturing safety and efficiency.

• Pharmaceutical X-Ray Counts Capsules And Pills

  8/15/2025

  See how advanced x-ray inspection technology verifies correct pill count, identifies broken capsules, and detects foreign contaminants in pharmaceutical sachet packets.

• Combining Powdose® And Diffucaps® For Precise Solid Oral Dosing

  6/30/2025

  Combining POWDOSE® and Diffucaps® enables precise, individualized solid oral dosing—improving drug delivery, patient compliance, and therapeutic outcomes in personalized medicine applications.

• Seizing Market Share Pre-Patent Expiry: The Evolution Of A CDMO Partnership In Navigating A Paragraph IV ANDA Submission

  6/26/2024

  The dynamic pharmaceutical landscape demands agility and strategic foresight. Explore how leveraging a key partnership helped to overcome a looming patent expiry for a second-generation acne medication.

• Closing The Duration Gap In FDA-Approved Long-Acting Contraceptives

  7/17/2024

  A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.